cisplatin,carboplatin,avelumab,pembrolizumab,atezolizumab,gemcitabine,Enfortumab vedotin
roche,merck,pfizer,astellas,Seagen
['muc ,(-much)', 'avelumab', 'pembro', 'atezo', 'cisplatin', 'imvigor 130', ' cis ', 'imvigor130', 'lba440', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'nct02807636', 'carboplatin', 'imvigor,11', 'bms']
#gu23 imvigor 130 final os: atezo + chemo vs chemo hr 0.85, non sig - consistent with other 1l io+chemo data (negative)
- carbo/gem arm vs prior benchmarks
- avelumab mnt = current io place in 1l combo setting
- will 1l chemo soon be challenged by pembro+ev? 
Medical Oncologist, @HamHealthSci | Assistant Professor, @McMasterU | Former Fellow, @DanaFarber | Academic focus: genitourinary & rare cancers | Views my own.